PubRank

Massimo Martino

Author PubWeight™ 17.63‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma. Biol Blood Marrow Transplant 2011 1.66
2 Feasibility of a mixed inpatient-outpatient model of peripheral blood stem cell transplantation for multiple myeloma. Haematologica 2002 1.49
3 Imatinib mesylate in T-cell large granular lymphocyte leukemia associated with chronic graft-versus-host disease. Leuk Lymphoma 2011 1.39
4 Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation. Leuk Res 2005 0.97
5 Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs. Br J Haematol 2013 0.96
6 The impact of early CD4+ lymphocyte recovery on the outcome of patients who undergo allogeneic bone marrow or peripheral blood stem cell transplantation. Blood Transfus 2012 0.88
7 High-dose chemotherapy for germ cell tumors: do we have a model? Expert Opin Biol Ther 2014 0.86
8 Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs. Expert Opin Biol Ther 2015 0.84
9 Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma. Transfusion 2013 0.83
10 Wernicke's encephalopathy after allogeneic stem cell transplantation. Tumori 2007 0.82
11 Identification of hematopoietic progenitor cell donor characteristics predicting successful mobilization: results of an Italian multicenter study. Transfusion 2014 0.80
12 Chimerism does not influence graft-versus-myeloma and graft-versus-host disease in reduced intensity setting. Transpl Immunol 2005 0.79
13 Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients. Br J Haematol 2003 0.79
14 Early measurement of CD34+ cells in peripheral blood after cyclophosphamide and granulocyte colony-stimulating factor treatment predicts later CD34+ mobilisation failure and is a possible criterion for guiding "on demand" use of plerixafor. Blood Transfus 2012 0.79
15 An old drug with a new future: bendamustine in multiple myeloma. Expert Opin Pharmacother 2013 0.78
16 A molecular and computational diagnostic approach identifies FOXP3, ICOS, CD52 and CASP1 as the most informative biomarkers in acute graft-versus-host disease. Haematologica 2012 0.77
17 Immune-related strategies driving immunotherapy in breast cancer treatment: a real clinical opportunity. Expert Rev Anticancer Ther 2015 0.77
18 Role of new drugs incorporated into consolidation and maintenance therapy in transplant-eligible multiple myeloma patients. Expert Opin Pharmacother 2014 0.76
19 Hematopoietic progenitor cells transplantation for recurrent or refractory Hodgkin's lymphoma. Expert Opin Biol Ther 2013 0.76
20 Smoldering multiple myeloma: to treat or not to treat. Expert Opin Pharmacother 2015 0.75
21 Modification of the content of plasma protein carbonyl groups in donors after granulocyte colony stimulating factor-induced stem cell mobilization. Transfus Apher Sci 2005 0.75
22 Different gamma/delta T clones sustain GVM and GVH effects in multiple myeloma patients after non-myeloablative transplantation. Leuk Res 2005 0.75
23 Plerixafor: what we still have to learn. Expert Opin Biol Ther 2014 0.75
24 Diagnostic approaches for identifying acute graft-versus-host disease: what comes next? Immunotherapy 2013 0.75